19054-Breast Cancer-NA-1270

Breast Cancer

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number:

  • Address

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

Search by practice name, trial titles, indicators and specific disease types.